We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mitochondrial Damage May Explain the Increased Incidence of Hypertension in Black Adults

By LabMedica International staff writers
Posted on 03 Mar 2022

Increased plasma concentration of the enzyme xanthine oxidase (XO) and the resulting mitochondrial DNA damage that it can cause may explain why Blacks have a significantly higher incidence of hypertension than their White counterparts. More...

Investigators at the University of Alabama (Birmingham, USA) had previously reported that increased plasma XO activity in patients with resistant hypertension could cause mitochondrial DNA damage and promote release of fragments called mitochondrial DNA damage-associated molecular patterns (mtDNA DAMPs). Xanthine oxidase is widely distributed in the heart, liver, gut, lung, kidney and brain, as well as in blood plasma. In its normal metabolic function, it generates oxygen radicals as a byproduct, including hydrogen peroxide and superoxide, which are reactive oxygen species that can damage DNA.

Considering that Black adults in the United States have one of the highest rates of hypertension in the world and have a 50% increased incidence of heart failure as compared to Whites, the investigators examined the importance of racial differences in XO activity and mtDNA DAMPs in adults with resistant hypertension.

The experimental cohort for this study included 91 resistant hypertension patients, 44% of whom were Black, and 37 controls with normal blood pressures. The resistant hypertension group all had blood pressures above 140/90 millimeters of mercury (mmHg), and all were on four or more medications for treatment of their high blood pressure.

Results revealed that Black resistant hypertension patients were younger (mean age 52±10 versus 59±10 years), with higher XO activity and left ventricular wall thickness, and worse diastolic dysfunction than White resistant hypertension patients. Urinary sodium excretion was positively related to left ventricular end-diastolic volume and left ventricular mass among Black but not White resistant hypertension patients. Patients with resistant hypertension had increased mtDNA DAMPs versus controls, with Black mtDNA DAMPS greater than Whites.

Transmission electron microscopy of skeletal muscle biopsies in resistant hypertension patients demonstrated mitochondrial damage such as cristae lysis, myofibrillar loss, large lipid droplets, and glycogen accumulation.

"Xanthine oxidase activation may set up a feed-forward cycle of mitochondrial damage, mitochondrial reactive oxygen species production, mtDNA DAMP release, and inflammation in the pathogenesis of hypertension end-organ injury," said senior author Dr. Louis J. Dell'Italia, professor emeritus of cardiovascular disease at the University of Alabama. "These results warrant a larger study that includes metabolic syndrome and xanthine oxidase as a potential therapeutic target to reduce mitochondrial damage and attenuate left ventricular diastolic dysfunction in Black adults with resistant hypertension. Although Black adults have the highest death rate for heart failure, they are consistently underrepresented in clinical trials. The greater heart failure burden among Black adults calls for further work to discover effective preventive and therapeutic strategies for this higher-risk population."

The study was published in the February 15, 2022, online edition of the journal Hypertension.

Related Links:
University of Alabama 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
Gel Cards
DG Gel Cards
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.